258
Participants
Start Date
August 1, 2023
Primary Completion Date
July 31, 2027
Study Completion Date
July 31, 2027
Sin-Bev-TACE
Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
Len-TACE
Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
RECRUITING
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Affiliated Hospital of Guangdong Medical University
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
Lecong Hospital, Shunde District, Foshan
UNKNOWN
First People's Hospital of Foshan
OTHER
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER